Latest | F'cast | |
---|---|---|
Div Yield | 0.9% | 0.0% |
Div Cover | 3.8 | n/a |
Op Mrgn | 9.1% | n/a |
ROCE | 8.2% |
Latest | F'cast | |
---|---|---|
P/E | 28.3 | n/a |
PEG | 2.5 | n/a |
Pr/Revenue | 0.7 | n/a |
Pr/Book | 1.3 |
Latest | F'cast | |
---|---|---|
Revenue | 11.2% | n/a |
PBT | 10.7% | n/a |
EPS | 11.4% | n/a |
DPS | 9.5% | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-20 | 919.90 | (231.00) | (5.20)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-21 | 1,106.20 | (1.90) | (7.10)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-22 | 1,198.50 | 3.90 | 4.20p | 54.3 | n/a | n/a | 0.50p | 0.2% |
31-Dec-23 | 1,359.00 | 34.60 | 7.90p | 28.7 | 0.3 | +88% | 2.10p | 0.9% |
31-Dec-24 | 1,511.20 | 38.30 | 8.80p | 25.7 | 2.3 | +11% | 2.30p | 1.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Form 8.5 (EPT/NON-RI)-Spire Healthcare Group plc | 07-Oct-2025 | 11:12 | RNS |
Form 8.5 (EPT/RI)-Spire Healthcare Group plc | 07-Oct-2025 | 11:10 | RNS |
Form 8.5 (EPT/NON-RI)-Spire Healthcare Group plc | 07-Oct-2025 | 11:09 | RNS |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 244.00p |
Change Today | 9.50p |
% Change | 4.05 % |
52 Week High | 249.00 |
52 Week Low | 171.40 |
Volume | 525,727 |
Shares Issued | 402.76m |
Market Cap | £982.73m |
Beta | 0.00 |
RiskGrade | 165 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Latest | Previous | |
---|---|---|
Final | Final | |
Ex-Div | 22-May-25 | 23-May-24 |
Paid | 20-Jun-25 | 21-Jun-24 |
Amount | 2.30p | 2.10p |
Time | Volume / Share Price |
12:00 | 1,818 @ 243.95p |
11:59 | 1,217 @ 244.15p |
11:57 | 2,000 @ 244.15p |
11:54 | 450 @ 244.21p |
11:53 | 714 @ 243.95p |
CEO | Justin Ash |
CFO | Harbant Samra |
You are here: research